Key Documents

View All Documentation

Orlistat

Name: Orlistat
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(−)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester, Ro-18-0647

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₂₉H₅₃NO₅

CAS Number:

96829-58-2

Molecular Weight:

495.73

NACRES:

NA.24

PubChem Substance ID:

329750618

UNSPSC Code:

41116107

MDL number:

MFCD05662360

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

orlistat

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

InChI key

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Gene Information

human ... LIPF(8513), PNLIP(5406)

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Solution is not completely clear, small particles may remain floating.

Sales restrictions may apply.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	PHR1445	O4139	1478811
USP 1478800 Orlistat	Supelco PHR1445 Orlistat	Sigma-Aldrich O4139 Orlistat	USP 1478811 Orlistat Related Compound A
manufacturer/tradename USP	manufacturer/tradename -	manufacturer/tradename -	manufacturer/tradename USP
grade pharmaceutical primary standard	grade certified reference material, pharmaceutical secondary standard	grade -	grade pharmaceutical primary standard
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) -	application(s) pharmaceutical (small molecule)
format neat	format neat	format -	format neat
Gene Information human ... LIPF(8513), PNLIP(5406)	Gene Information human ... LIPF(8513), PNLIP(5406)	Gene Information human ... LIPF(8513), PNLIP(5406)	Gene Information -
API family orlistat	API family orlistat	API family -	API family orlistat

Still not finding the right product?

Explore all of our products under Orlistat

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Orlistat: a review of its use in the management of obesity.

Sheridan Henness et al.

Drugs, 66(12), 1625-1656 (2006-09-08)

Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data

The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.

Walmir Coutinho

Arquivos brasileiros de endocrinologia e metabologia, 53(2), 262-270 (2009-05-26)

Ancillary therapies for weight management, consisting mainly of diet and exercise programs that incorporate variable levels of lifestyle modification techniques, are frequently ineffective to achieve clinically meaningful weight loss and maintenance. Although pharmacological treatment of obesity is widely used in

Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage.

James W Anderson

Expert opinion on pharmacotherapy, 8(11), 1733-1742 (2007-08-10)

Orlistat, in the 60-mg over-the-counter dose, was recently approved by the FDA. This lipase inhibitor blocks absorption of ~25% of ingested fat and has ~85% of the efficacy of the 120-mg dose for weight loss. Over 16 weeks weight loss

View All Related Papers

Global Trade Item Number

SKU	GTIN
1478800-200MG	04061838737694

Questions

Reviews

No rating value